SCHEMBL1999579

SCHEMBL1999579

Cc1ccc2nc(Oc3cc(Cl)cc(NC(=O)OC(C)(C)C)c3)sc2c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 8/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
P2RX3 P56373 2/20 0.42
DYRK1A Q13627 1/20 0.41
CTSD P07339 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
KMT2A Q03164 1/20 0.40
RELA Q04206 1/20 0.40
MAP3K5 Q99683 1/20 0.40
CSNK1D P48730 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2001470 0.92 DYRK1A (0.44) LCKP2RX3DYRK1ACTSDNPC1
SCHEMBL2005135 0.90 LRRK2 (0.43) LCKP2RX3DYRK1ACTSDSMN1; SMN2
SCHEMBL1999982 0.89 NPC1 (0.45) DYRK1ACTSDNPC1RAB9ASMN1; SMN2
SCHEMBL12568203 0.88 CTSD (0.52) LCKCTSDSMN1; SMN2
SCHEMBL2000055 0.86 NPC1 (0.48) LCKNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL1997495 0.86 AGPAT2 (0.45) LCKP2RX3DYRK1ACTSD
SCHEMBL2000936 0.82 LCK (0.42) LCKCTSDMEN1ALDH1A1HPGD
SCHEMBL2002719 0.82 AGPAT2 (0.47) LCKP2RX3DYRK1ACTSD
SCHEMBL18580398 0.82 CTSD (0.49) LCKP2RX3DYRK1ACTSDNPC1
SCHEMBL2003618 0.82 AGPAT2 (0.46) LCKL3MBTL1CTSDKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960408-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2011-06-14 US disclosed
US-7601841-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2009-10-13 US disclosed
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. (US) 2009-09-03 US disclosed
EP-1296967-B1 BENZOTHIAZOLYL PPAR-GAMMA MODULATORS AMGEN INC (US) 2006-05-31 EP disclosed
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC 2004-09-09 US disclosed
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC. 2003-09-11 US disclosed
US-6583157-B2 Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders TULARIK INC. 2003-06-24 US disclosed
EP-1296967-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS Tularik Inc. (US) 2003-04-02 EP disclosed
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. 2002-11-14 US disclosed
WO-2002000633-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS TULARIK INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD LCK 2880/4885L3MBTL1 3621/4885P2RX3 587/4885
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD LCK 2880/4885L3MBTL1 3621/4885P2RX3 587/4885
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARA, PPARG, PPARD LCK 2880/4885L3MBTL1 3621/4885P2RX3 587/4885
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARG, PPARA, PPARD LCK 2698/4885L3MBTL1 3303/4885P2RX3 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.